Document Type : Original Article
Authors
1
Clinical Hematology Unit, Internal Medicine Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
2
Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt.
3
Internal Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt.
4
Internal Medicine and Clinical Hematology Unit, Assiut University Hospitals, South Egypt Cancer Institute Bone Marrow Transplantation, Faculty of Medicine, Assiut University, Assiut, Egypt.
Abstract
Abstract
Background and Aim: The expression of CD56 and CD200 has emerged as novel biomarkers for predicting the prognosis of individuals with acute myeloid leukemia. The study aims to examine CD200 and CD56 expression among patients with AML.
Patients and Methods: We enrolled 51 recently diagnosed with (non-M3-denovo) AML. Baseline demographic, clinical, and laboratory information was collected. The expression of CD200 and CD56 was measured by flow cytometry.
Results: The average age of the patients was 49.23. Fifteen (29.4%), ten (19.6%), and ten (19.6%) patients had CD200, CD56, and CD200/CD56 expression, respectively. Overall survival was significantly better among patients with negative CD200 expression (9.11 vs. 3.22 (months); p < 0.001). Also, patients with negative CD200 expression had significantly better DFS (10.11 vs. 5.56 (months); p= 0.01). Also, overall survival was significantly better among those with negative CD56 expression (8.80 vs. 2.65 (months); p < 0.001) and better DFS (10.04 vs. 6.11 (months); p= 0.02).
Conclusion: Overall, our findings suggest that high levels of CD200 and CD56 expression are associated with a poor prognosis in newly diagnosed AML patients. These findings indicate that CD200 and CD56 could be targets for targeted AML therapy, particularly in patients with CD200 and CD56 overexpression. More clinical and experimental evidence will be required to confirm these findings.
Keywords
)
View on SCiNiTO